YM BioSciences, Inc. (AMEX: YMI)

YM BioSciences, Inc. (AMEX: YMI), an oncology company, is focused on identifying, developing and commercializing a variety of products for patients on a global basis. The Company is advancing two late-stage products: Nimotuzumab, a humanized monoclonal antibody designed to target the epidermal growth factor receptor (EGFR); and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. Nimotuzumab has received approval in multiple countries for treating types of head and neck cancer, while AeroLEF is in development for the treatment of moderate to severe pain. For further information, visit the Company’s web site at www.ymbiosciences.com.